Paris, London and Milan-based Sofinnova Partners has recently announced the closing of their oversubscribed late-stage healthcare crossover fund at €445 Million. This now comprises the largest crossover investor dedicated late-stage biopharma and medtech fund in Europe.
Sofinnova is expected to Maintain their focus on European companies in need of scale-up capital, but will also support firms in the US and “elsewhere”.
To date, the fund has invested in 10 companies, each developing products meeting industry needs. Sofinnova reports that the majority of these investments from reached positive clinical trial milestones, with two investments launching NASDAQ IPOs.
“European biopharma and medtech companies have matured tremendously in the last decade. Sofinnova Partners was the first European VC to seize the opportunity to unlock the potential of these high-growth start-ups by providing late-stage capital, building on our decades of experience funding innovative life science companies,” comments Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners.
“With over €2 billion of assets under management dedicated to life science investing and an outstanding international team, Sofinnova Partners continues its expansion to partner with ambitious entrepreneurs across Europe, from company creation to late-stage developments.”